← All trials
NCT06200844
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Jan 11, 2024
- Last posted
- Jan 11, 2024
- Enrollment
- 5800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bharat Biotech International LimitedLead sponsor
- Bharat Biotech International LimitedOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.